Treatment with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone is beneficial but toxic in very elderly patients with diffuse large B-cell lymphoma: a population-based cohort study on treatment, toxicity and outcome

References

• Thieblemont C, Grossoeuvre A, Houot R, et al. Non-Hodgkin's lymphoma in very elderly patients over 80 years. A descriptive analysis of clinical presentation and outcome. Ann Oncol 2008;19:774–779.
   Google Scholar
• Maartense E, Kluin-Nelemans HC, Noordijk EM. Non-Hodgkin's lymphoma in the elderly. A review with emphasis on elderly patients, geriatric assessment, and future perspectives. Ann Hematol 2003;82:661–670.
   Google Scholar
• Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235–242.
   PubMed Web of Science ®Google Scholar
• Coiffier B, Thieblemont C, Van Den Neste E, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d’Etudes des Lymphomes de l’Adulte. Blood 2010;116:2040–2045.
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Schubert J, Ziepert M, et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20 + B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol 2008;9:105–116.
   PubMed Web of Science ®Google Scholar
• van de Schans SA, Wymenga AN, van Spronsen DJ, et al. Two sides of the medallion: poor treatment tolerance but better survival by standard chemotherapy in elderly patients with advanced-stage diffuse large B-cell lymphoma. Ann Oncol 2012;23:1280–1286.
   PubMed Web of Science ®Google Scholar
• Hoogendoorn M, Joosten P, Storm H, et al. HemoBase: een intelligent elektronisch patiëntendossier als coach voor de hemato-oncologische zorg. Nederlands tijdschrift voor hematologie. 2009;6:104–110.
   Google Scholar
• Swerdlow SH, Campoo E, Harris NL. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC; 2008.
   Google Scholar
• National Cancer Institute. Common Terminology Criteria for Adverse Events. NIH. 2006. Available from: http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf
   Google Scholar
• Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579–586.
   PubMed Web of Science ®Google Scholar
• Maartense E, Hermans J, Kluin-Nelemans JC, et al. Elderly patients with non-Hodgkin's lymphoma: population-based results in The Netherlands. Ann Oncol 1998;9:1219–1227.
   PubMed Web of Science ®Google Scholar
• Peters FP, Lalisang RI, Fickers MM, et al. Treatment of elderly patients with intermediate- and high-grade non-Hodgkin's lymphoma: a retrospective population-based study. Ann Hematol 2001;80:155–159.
   PubMed Web of Science ®Google Scholar
• Doorduijn JK, van der Holt B, van Imhoff GW, et al. CHOP compared with CHOP plus granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin's lymphoma. J Clin Oncol 2003;21:3041–3050.
   PubMed Web of Science ®Google Scholar
• Sehn LH, Donaldson J, Chhanabhai M, et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol 2005;23:5027–5033.
   PubMed Web of Science ®Google Scholar
• Peyrade F, Jardin F, Thieblemont C, et al. Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial. Lancet Oncol 2011;12:460–468.
   PubMed Web of Science ®Google Scholar
• Morrison VA. Non-Hodgkin's lymphoma in the elderly. Part 2: treatment of diffuse aggressive lymphomas. Oncology (Williston Park) 2007;21:1191–1198; discussion 1198–1208, 1210.
   Google Scholar
• Aapro MS, Bohlius J, Cameron DA, et al. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 2011;47:8–32.
   PubMed Web of Science ®Google Scholar
• Smith TJ, Khatcheressian J, Lyman GH, et al. 2006 Update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006;24: 3187–3205.
   PubMed Web of Science ®Google Scholar
• Chrischilles E, Delgado DJ, Stolshek BS, et al. Impact of age and colony-stimulating factor use on hospital length of stay for febrile neutropenia in CHOP-treated non-Hodgkin's lymphoma. Cancer Control 2002;9:203–211.
   PubMedGoogle Scholar
• Osby E, Hagberg H, Kvaloy S, et al. CHOP is superior to CNOP in elderly patients with aggressive lymphoma while outcome is unaffected by filgrastim treatment: results of a Nordic Lymphoma Group randomized trial. Blood 2003;101:3840–3848.
   PubMed Web of Science ®Google Scholar
• Doorduijn JK, van der Holt B, van Imhoff GW, et al. CHOP compared with CHOP plus granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin's lymphoma. J Clin Oncol 2003;21:3041–3050.
   PubMed Web of Science ®Google Scholar
• Cullen M, Steven N, Billingham L, et al. Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas. N Engl J Med 2005;353:988–998.
   PubMed Web of Science ®Google Scholar
• Bucaneve G, Micozzi A, Menichetti F, et al. Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. N Engl J Med 2005;353:977–987.
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M. How I treat elderly patients with diffuse large B-cell lymphoma. Blood 2010;116:5103–5110.
   PubMed Web of Science ®Google Scholar
• Bonadio M, Morelli G, Mori S, et al. Fluoroquinolone resistance in hematopoietic stem cell transplant recipients with infectious complications. Biomed Pharmacother 2005;59:511–516.
   PubMed Web of Science ®Google Scholar
• Mora O, Zucca E. Management of elderly patients with hematological neoplasms. Ann Oncol 2007;18(Suppl. 1):i49–i53.
   PubMed Web of Science ®Google Scholar
• Link BK, Brooks J, Wright K, et al. Diffuse large B-cell lymphoma in the elderly: diffusion of treatment with rituximab and survival advances with and without anthracyclines. Leuk Lymphoma 2011;52:994–1002.
   PubMed Web of Science ®Google Scholar
• Musolino A, Boggiani D, Panebianco M, et al. Activity and safety of dose-adjusted infusional cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy with rituximab in very elderly patients with poor-prognostic untreated diffuse large B-cell non-Hodgkin lymphoma. Cancer 2011;117:964–973.
   PubMed Web of Science ®Google Scholar
• Hainsworth JD, Flinn IW, Spigel DR, et al. Brief-duration rituximab/chemotherapy followed by maintenance rituximab in patients with diffuse large B-cell lymphoma who are poor candidates for R-CHOP chemotherapy: a phase II trial of the Sarah Cannon Oncology Research Consortium. Clin Lymphoma Myeloma Leuk 2010;10:44–50.
   PubMed Web of Science ®Google Scholar
• Walter E, Schmitt T, Dietrich S, et al. Rituximab and bendamustine in patients with CD20 + diffuse large B-cell lymphoma not eligible for cyclophosphamide, doxorubicin, vincristine and prednisone-like chemotherapy. Leuk Lymphoma 2012;53:2290–2292.
   PubMed Web of Science ®Google Scholar
• Tucci A, Ferrari S, Bottelli C, et al. A comprehensive geriatric assessment is more effective than clinical judgment to identify elderly diffuse large cell lymphoma patients who benefit from aggressive therapy. Cancer 2009;115:4547–4553.
   PubMed Web of Science ®Google Scholar
• Winkelmann N, Petersen I, Kiehntopf M, et al. Results of comprehensive geriatric assessment effect survival in patients with malignant lymphoma. J Cancer Res Clin Oncol 2011;137:733–738.
   PubMed Web of Science ®Google Scholar
• Aaldriks AA, Maartense E, le Cessie S, et al. Predictive value of geriatric assessment for patients older than 70 years, treated with chemotherapy. Crit Rev Oncol Hematol 2011;79:205–212.
   PubMed Web of Science ®Google Scholar
• Caillet P, Canoui-Poitrine F, Vouriot J, et al. Comprehensive geriatric assessment in the decision-making process in elderly patients with cancer: ELCAPA study. J Clin Oncol 2011;29:3636–3642.
   PubMed Web of Science ®Google Scholar
• Lin TL, Kuo MC, Shih LY, et al. The impact of age, Charlson comorbidity index, and performance status on treatment of elderly patients with diffuse large B cell lymphoma. Ann Hematol 2012;91: 1383–1391.
   PubMed Web of Science ®Google Scholar
• Kobayashi Y, Miura K, Hojo A, et al. Charlson Comorbidity Index is an independent prognostic factor among elderly patients with diffuse large B-cell lymphoma. J Cancer Res Clin Oncol 2011;137: 1079–1084.
   PubMed Web of Science ®Google Scholar
• Saliba D, Elliott M, Rubenstein LZ, et al. The Vulnerable Elders Survey: a tool for identifying vulnerable older people in the community. J Am Geriatr Soc 2001;49:1691–1699.
   PubMed Web of Science ®Google Scholar
• Schuurmans H, Steverink N, Lindenberg S, et al. Old or frail: what tells us more?J Gerontol A Biol Sci Med Sci 2004;59: M962–M965.
   PubMed Web of Science ®Google Scholar
• Scher KS, Hurria A. Under-representation of older adults in cancer registration trials: known problem, little progress. J Clin Oncol 2012;30:2036–2038.
   PubMed Web of Science ®Google Scholar